Psychedelic Science Newsletter
Issue #61October 26, 20267 studies

A single IV ketamine dose cut depression and suicidal ideation scores in teens stuck in the ER

The mental health research pipeline had a busy week — new trial data, sharp methodological critiques, and one very unexpected worm study.

Here's what moved the needle.

🏥 Ketamine in the pediatric ER: a randomized trial finally tests it

  • Adolescents with treatment-resistant depression and suicidal ideation often spend days boarding in emergency departments with no active treatment. This double-blind, placebo-controlled trial tested whether a single IV ketamine dose could change that.
  • Compared to placebo, ketamine produced meaningfully larger reductions in both depression scores and suicidal ideation — a population where almost nothing has been tested in a controlled setting.
  • The trial is small and the setting is unusual, but it's one of the first randomized controlled trials to directly test a rapid-acting antidepressant in suicidal youth in an acute care environment.

Why it matters: Boarding adolescents in ERs without treatment is the default precisely because options are so limited. This is early evidence that the default might not have to hold.

Top 30% journal 🔗 The western journal of emergency medicine Randomized Controlled Trial 🗓️ Oct 20

Key Findings

📰 Psilocybin media coverage is running ahead of the evidence

  • A systematic review in JAMA Network Open found that news media reporting on psilocybin clinical trials consistently fails to reflect the methodological limitations of the underlying studies.
  • Small samples, short follow-up periods, and functional unblinding are common in the trial literature — but largely absent from headlines.
💡 The psilocybin hype cycle has a measurable gap from the science.
🥈 Top 2% journal 🔗 JAMA network open Systematic Review 🗓️ Oct 20

🍄 Psilocybin linked to lower inflammation markers in Parkinson's patients

  • A nonrandomized clinical trial published in JAMA Psychiatry found that psilocybin therapy was associated with changes in systemic markers of inflammation and mitochondrial stress in people with Parkinson's disease and mood dysfunction.
  • The nonrandomized design means causation can't be established, but the signal — connecting a psychedelic to biological stress markers in a neurodegenerative condition — is new enough to watch.
💡 Psilocybin's reach into neurodegeneration biology is just starting to be mapped.
🥇 Top 1% journal 🔗 JAMA psychiatry Journal Article 🗓️ Oct 22

🍺 Psilocybin for alcohol use disorder holds up in open-label extension

  • Patients who completed a blinded Phase II randomized controlled trial of psilocybin-assisted therapy for alcohol use disorder were then offered open-label treatment. Safety and efficacy outcomes from that extension suggest continued benefit.
  • The study can't isolate how much of the effect comes from expectancy versus the drug, but it adds durability data to a trial base that has been light on long-term follow-up.
💡 Open-label data suggests psilocybin's alcohol use benefits may extend beyond the blinded trial window.
🎖️ Top 10% journal 🔗 Drug and alcohol dependence Journal Article 🗓️ Oct 23

⚖️ Ketamine is cost-effective versus electroconvulsive therapy for hard-to-treat depression

  • A cost-effectiveness analysis found that racemic ketamine compares favorably to electroconvulsive therapy for non-psychotic treatment-resistant depression when outcomes are measured as quality-adjusted life-years.
  • Electroconvulsive therapy is highly effective but carries cognitive side-effect concerns and access barriers. Ketamine's cleaner side-effect profile and lower logistical burden may shift the calculus for some patients.
💡 Ketamine's cost-effectiveness case against electroconvulsive therapy now has formal modeling behind it.
🔗 Psychiatric services (Washington, D.C.) Journal Article 🗓️ Oct 22

🪱 LSD extended lifespan in worms by up to 17.6% — with caveats

  • Chronic exposure to nanomolar concentrations of LSD extended lifespan in the roundworm C. elegans by up to 17.6% at the 25% survival timepoint, and reduced age-associated cellular waste accumulation.
  • The effect was tied to serotonergic receptor signaling and overlapped with caloric restriction phenotypes — smaller body size, reduced reproduction — though feeding rates weren't detectably reduced. This is a worm study, not a human one.
💡 LSD touches longevity-related biology in worms, but the distance to humans is vast.
Top 20% journal 🔗 Biogerontology Journal Article 🗓️ Oct 23

🔬 Researchers found a new druggable pocket in the brain's main psychedelic receptor

  • Molecular modeling and lab experiments identified a hydrophobic tunnel adjacent to the main binding site of the serotonin 2A receptor — the primary target for serotonergic psychedelics.
  • Compounds with substituents of at least four heavy atoms at a specific position on the phenyl ring were able to reach into this tunnel and increase their potency at the receptor, pointing toward a structural feature that drug designers hadn't fully exploited.
💡 A newly mapped receptor pocket could reshape how next-generation psychedelic compounds are designed.
🎖️ Top 10% journal 🔗 Journal of medicinal chemistry Journal Article 🗓️ Oct 23

Implications

Psychedelic and ketamine research is producing real trial data now — but the methodological critiques are keeping pace. The unresolved tension: as open-label extensions and small trials accumulate, the field still lacks large, long-term studies that can separate drug effects from expectancy and therapeutic context.

Studies in this issue

Primary sources used for this newsletter.

  1. LSD may lengthen lifespan in a type of worm
    key findingBiogerontology2026-10-23PMID 42911464